SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing

Athina Mavrou, Sebastian Oltean

Research output: Contribution to journalArticle (Academic Journal)peer-review

12 Citations (Scopus)
291 Downloads (Pure)

Abstract

Prostate cancer remains one of the leading causes of cancer death in men around the world, regardless of intense research and development of novel therapies in the last 10 years. One of the new avenues that has been tested − inhibition of angiogenesis − has been disappointing so far in clinical studies in spite of strong evidence that determinants of angiogenesis (e.g vascular endothelial growth factor) are strongly associated with disease progression. One of the reasons for these outcomes may be our poor understanding of the biology of angiogenesis in prostate cancer (and probably other cancers as well) resulting in inhibition of both detrimental and favourable molecules. We discuss here novel targeted and more specific approaches to inhibit angiogenesis in prostate cancer as well as a completely new therapeutic modality to do this − modulation of alternative splicing − that may be applicable to other molecules/biological processes as well.
Original languageEnglish
Pages (from-to)276-281
Number of pages6
JournalPharmacological Research
Volume107
Early online date16 Mar 2016
DOIs
Publication statusPublished - May 2016

Keywords

  • Prostate cancer
  • Angiogenesis
  • Alternative splicing
  • Novel therapeutics

Fingerprint Dive into the research topics of 'SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing'. Together they form a unique fingerprint.

Cite this